All News #Library
Rare Diseases
Tiziana Starts Ph 2a Trial of Intranasal Foralumab in MSA
15 Aug 2025 //
PHARMAWEB
Tiziana Doses First Patient in Phase 2a Trial of Intranasal
14 Aug 2025 //
GLOBENEWSWIRE
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
13 May 2024 //
GLOBENEWSWIRE

Market Place
Sourcing Support